Tapinarof, a novel, first-in-class, small-molecule topical therapeutic aryl hydrocarbon receptor (AhR)–modulating agent, is in clinical development for the treatment of psoriasis and atopic dermatitis. The efficacy of tapinarof in psoriasis is attributed to its specific binding and activation of AhR, a ligand-dependent transcription factor, leading to the downregulation of proinflammatory cytokines, including interleukin 17, and regulation of skin barrier protein expression to promote skin barrier normalization. AhR signaling regulates gene expression in immune cells and skin cells and has critical roles in the regulation of skin homeostasis. Tapinarof-mediated AhR signaling underlies the mechanistic basis for the significant efficacy and acceptable tolerability observed in early-phase clinical trials of tapinarof cream in the treatment of psoriasis.

Tapinarof 是一种新型的、一流的、小分子局部治疗性芳烃受体 (AhR) 调节剂，正在临床开发中用于治疗银屑病和特应性皮炎。Tapinarof 在银屑病中的疗效归因于其特异性结合和激活 AhR（一种配体依赖性转录因子），导致促炎细胞因子（包括白细胞介素 17）的下调和皮肤屏障蛋白表达的调节以促进皮肤屏障正常化。AhR 信号调节免疫细胞和皮肤细胞中的基因表达，并且在调节皮肤稳态中具有关键作用。